|
|||||
|
|
HIV-1 Clinical Isolates with the E138A Substitution in Reverse Transcriptase Show Full Susceptibility to Emtricitabine and Other Nucleoside Reverse Transcriptase Inhibitors |
|
| Authors: | Danielle P. Porter Rima Kulkarni Kirsten L. White |
| Affiliation: | Gilead Sciences, Inc., Foster City, California, USA |
| Abstract: | |
| Keywords: | |